Effect of miRNAs in serum exosomal on microvascular invasion of hepatocellular carcinoma and its mechanism

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000039785

Enrollment

Unknown

Registered

2020-11-09

Start date

2020-12-01

Completion date

Unknown

Last updated

2021-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

Gold Standard:Pathology

Index test:expression&#32

of&#32

miRNA&#32

in&#32

serum&#32

exosomal

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: From December 2020 to October 2022, the patients with complete data were diagnosed as primary hepatocellular carcinoma (HCC) with tumor resection in our hospital.

Exclusion criteria

Exclusion criteria: 1. Under the age of 18 years. 2. Patients with severe heart, liver, lung, kidney, immunity, blood system diseases and cerebrovascular diseases. 3. Patients with severe acute inflammation and mental illness. 4. Patients with two or more tumors. 5. Patients who have received any adjuvant radiotherapy, chemotherapy and other antineoplastic therapy before operation. 6. Patients who rejected this study.

Design outcomes

Primary

Measure	Time frame
SEN, SPE, ACC, AUC of ROC;	—

Countries

China

Contacts

Public ContactDousheng Bai

Subei People's Hospital of Jiangsu Province

drbaidousheng@163.com+86 18051062858

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026